Fig. 2
From: ERβ mediates sex-specific protection in the App-NL-G-F mouse model of Alzheimer’s disease
Less Aβ pathology in AppNL−G−F male and female mice after ERβ activation. A Immunohistochemical representation of amyloid plaques in frontal and motor cortex (FT/M), somatosensory and visual cortex (Ss/Vis) and hippocampus (Hippoc) of male AppNL−G−F mice after vehicle or LY treatment. B Quantification of number of plaques per 100 µm2 (n = 4–6) and C percent plaque area (n = 4–6) in male AppNL−G−F mice. D Similar as in A, immunohistochemical representation of amyloid plaques in different brain regions of female AppNL−G−F mice after vehicle or LY treatment. E Quantification of number of plaques per 100 µm2 (n = 4–5) and F percent plaque area (n = 4–9) in female AppNL−G−F mice. G Linear regression analysis comparing effect size from LY treatment (vehicle vs. LY) on number of Aβ plaques in relation to average number of ERβ positive cells per 100 µm2 in different brain regions of male and female mice (n = 4–6). H Soluble and (I) insoluble Aβ42 levels in male cortex (Ctx, left) and hippocampus (Hippoc, right) (n = 3–4). (J) Soluble and (K) insoluble Aβ42 levels in female cortex (left) and hippocampus (right) (n = 3). * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001. Unpaired t-test was used for males and 2-way ANOVA for females followed by uncorrected Fisher’s LSD test for multiple comparisons. Overall significant main effects of treatment or OVX are indicated. Scale bars = 100 µm